DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05936151

CompletedPhase 2

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

42

Recruiting sites

—

Enrollment

146

actual

Study population

Chronic kidney disease, Obesity / overweight

Key I/E criteria

•BMI ≥27•HbA1c ≤6.5%

Primary endpoint

•EGFR, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05936151
Org study ID18725
Secondary ID2023-504583-42-00EU Trial Number
Secondary IDJ1I-MC-GZBUEli Lilly and Company

Timeline

Milestones

Study first posted2023-07-07actual
Study start2023-07-20actual
Primary completion2025-10-01actual
Study completion2025-10-21actual
Last update posted2025-11-25actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Chronic kidney diseaseObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Have a body mass index (BMI) ≥27 kilogram/square meter (kg/m²)
•Have either
–no T2D with an HbA1c < 6.5% or
–have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.
•Have been diagnosed with chronic kidney disease (CKD).

Exclusion criteria

•Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening.
•Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin
•Have a prior or planned surgical treatment for obesity
•Have Type 1 Diabetes (T1D)
•Have acute or chronic hepatitis
•Have a history of malignant disease within 5 years before screening.

Endpoints (18)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Renal / kidney
14
Other (unclassified)
3
Weight & body composition
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Change from Baseline in Body Weight

Time frame:Baseline, Week 24

Body weight, absolute change (kg)

change from baseline, improvement

Renal / kidney

14 endpoints
Primary/protocol endpoint

Change from Baseline in Glomerular Filtration Rate (mGFR)

Time frame:Baseline, Week 24

eGFR, change

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Urine Albumin-to-Creatinine Ratio (UACR)

Time frame:Baseline, Week 24

uACR, change

change from baseline, improvement

LOINC 9318-7

Secondary/protocol endpoint

Change from Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from Baseline in Renal Artery Resistive Index (RARI)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) and End-diastolic Velocity (ESV)

Time frame:Baseline, Week 24

change from baseline, improvement

componentsrenal blood flow velocity peak systolic, renal blood flow velocity end diastolic

Secondary/protocol endpoint

Change from Baseline in Global Renal Perfusion (MRI)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Total Renal Parenchyma Volume (MRI)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Renal Cortex Volume (MRI)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Renal Cortex T1 (ms) (MRI)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Medulla T1 (ms) (MRI)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change from Baseline in Renal Cortex R2 (BOLD MRI)

Time frame:Baseline, Week 24

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in 24-hr Urinary Albumin Excretion (UAE)

Time frame:Baseline, Week 24

uACR, change

change from baseline, improvement

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Change from Baseline in in Mean Arterial Flow (MAF)

Time frame:Baseline, Week 24

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change from Baseline in Medulla R2

Time frame:Baseline, Week 24

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Change from Baseline in Change in 24-hour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h))

Time frame:Baseline, Week 24

change from baseline, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.